A human beta cell line with drug inducible excision of immortalizing transgenes
A human beta cell line with drug inducible excision of immortalizing transgenes
复制标题
DOI:
10.1016/j.molmet.2015.09.008
复制
发表时间:
2015-12-01
影响因子:
8.1
通讯作者:
Ravassard, Philippe
中科院分区:
文献类型:
--
作者:
Benazra, Marion;Lecomte, Marie-Jose;Ravassard, Philippe
Objectives: Access to immortalized human pancreatic beta cell lines that are phenotypically close to genuine adult beta cells, represent a major tool to better understand human beta cell physiology and develop new therapeutics for Diabetes. Here we derived a new conditionally immortalized human beta cell line, EndoC-beta H3 in which immortalizing transgene can be efficiently removed by simple addition of tamoxifen.Methods: We used lentiviral mediated gene transfer to stably integrate a tamoxifen inducible form of CRE (CRE-ERT2) into the recently developed conditionally immortalized EndoC beta H2 line. The resulting EndoC-beta H3 line was characterized before and after tamoxifen treatment for cell proliferation, insulin content and insulin secretion.Results: We showed that EndoC-beta H3 expressing CRE-ERT2 can be massively amplified in culture. We established an optimized tamoxifen treatment to efficiently excise the immortalizing transgenes resulting in proliferation arrest. In addition, insulin expression raised by 12 fold and insulin content increased by 23 fold reaching 2 mu g of insulin per million cells. Such massive increase was accompanied by enhanced insulin secretion upon glucose stimulation. We further observed that tamoxifen treated cells maintained a stable function for 5 weeks in culture.Conclusions: EndoC beta H3 cell line represents a powerful tool that allows, using a simple and efficient procedure, the massive production of functional non-proliferative human beta cells. Such cells are close to genuine human beta cells and maintain a stable phenotype for 5 weeks in culture. (C) 2015 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY license (http://creativecommons. org/licenses/by/4.0/).